Mometasone furoate, prodrug of the free form mometasone, is a agent with high affinity for the glucocorticoid receptor.IC50 value: Target: glucocorticosteroid receptorMometasone furoate is used in the treatment of inflammatory skin disorders (such as eczema and psoriasis), allergic rhinitis (such as hay fever), asthma [1]. MF is approved for once or bid maintenance treatment of asthma (in patients previously receiving ICS or bronchodilators). Low systemic bioavailability and high relative binding affinity for the glucocorticoid receptor are properties of MF that allow for a favourable efficacy and tolerability profile. Inhaled MF has been shown to be an effective and well-tolerated controller medication for those patients with mild, moderate or severe persistent asthma [2].
References:
[1]. Tan RA, et al. Mometasone furoate in the management of asthma: a review. Ther Clin Risk Manag. 2008 Dec;4(6):1201-8.
[2]. Bousquet J. Mometasone furoate: an effective anti-inflammatory with a well-defined safety and tolerability profile in the treatment of asthma. Int J Clin Pract. 2009 May;63(5):806-19.